The American Diabetes Association's 80th Scientific Sessions kicked off this weekend, and a handful of diabetes management device-makers and service providers highlighted new data as part of the virtual clinical conference. Read on for summaries of the studies and findings, as well as links to the online abstracts.
Onduo
Verily-backed diabetes management service Onduo, which combines a mobile app...
Dublin-based medical technology company Medtronic has acquired digital health startup Klue, a two-year-old startup which uses gesture sensing and other behavioral health metrics to determine when someone is eating. Nothing was disclosed about the terms of the deal, except that Medtronic considers it to be immaterial to 2020 earnings per share.
"Bringing Klue and their unique meal detection...
A recent paper published in Diabetes Technology & Therapeutics describes the design, safety and basic efficacy of a device-agnostic smartphone app that can interface with continuous glucose monitors, insulin pump devices and dosing algorithms from various manufacturers. Run on an unlocked smartphone, the interoperable Artificial Pancreas System (iAPS) smartphone app was reliable and generally...
Pediatric and adult Type 1 diabetes patients receiving a hybrid closed-loop artificial pancreas therapy demonstrated improved glucose control and lower risk of hypoglycemia compared to those managing their own glucose levels with an insulin pump and continuous glucose monitor, according to a study published today in the Lancet.
The investigation, which was supported by JDRF and presented at the...
The FDA has expanded its indication for Medtronic’s Guardian Sensor 3, allowing patients to wear the sensor on their upper arm.
The sensor is part of Medtronic’s MiniMed 670G system, and is currently the only continuous glucose monitor approved by the FDA to control automated insulin delivery via a hybrid closed loop system. Along with the added convenience of the new sensor site, the company...
Touchscreen insulin pump maker Tandem Diabetes announced a new clinical trial for an insulin pump with a predictive low glucose suspend (PLGS) algorithm. Another step on the road to an artificial pancreas, PLGS allows Tandem to automatically suspend insulin delivery when it predicts low glucose and resume it when glucose starts to rise again.
“The start of this pivotal trial is another important...
A new partnership in the diabetes space could bring the promise of an artificial pancreas closer to reality. Senseonics, a Germantown, Maryland company working on a pill-sized, implantable continuous glucose monitor that can last 90 days without needing replacement, will work with digital, personalized medicine company TypeZero Technologies on a project to integrate readings from Senseonics...
As exciting as the near future of diabetes management is, with numerous efforts underway to perfect closed-loop CGM and pump systems for automated insulin delivery, the systems of the future could be even easier. A paper out yesterday in Science Advances details the prototype for a 4 millimeter wearable patch that could not only noninvasively detect glucose levels from sweat, but also deliver the...
